Literature DB >> 32115732

The Wuhan SARS-CoV-2-What's next for China.

Hongzhou Lu1, Charles W Stratton2, Yi-Wei Tang3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32115732      PMCID: PMC7233262          DOI: 10.1002/jmv.25738

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


× No keyword cloud information.
When an outbreak of pneumonia of unknown etiology occurred in Wuhan City, Hubei Province, China, in December 2019, the mystery was the nature of the causative agent. As many of the patients had visited a fish and wild animal market, the possibility of a recurrence of severe acute respiratory syndrome (SARS) needed to be investigated. Finally, could this outbreak of pneumonia be caused by a novel coronavirus that was different from those causing SARS or Middle East respiratory syndrome (MERS) ? Once this outbreak was recognized as a serious threat, a special team consisting of physicians, scientists, and epidemiologists began to investigate these possibilities. Within 9 days, SARS and MERS had been ruled out and a novel coronavirus had been isolated in Wuhan; this coronavirus is now officially named as the SARS‐CoV‐2 by the International Committee on Taxonomy of Viruses. The breadth and nature of the investigation that identified this novel SARS‐CoV‐2 is elaborately described by Zhu and colleagues in a recent publication in The New England Journal of Medicine. Additional details subsequently have been published in several prestigious journals. , , , , , , , , , This study is quite remarkable and praiseworthy. Given the subsequent spread to other parts of China as well as to other countries, the reasons for this spread should be examined. There are two such reasons that are noteworthy. The first is that the potential threat of these initial cases of pneumonia was not well‐appreciated. The second reason is simply the timing of this outbreak; the outbreak began just before the Chinese New Year. By the time the investigation had been completed, the Chinese New Year was underway. The Chinese New Year is one of the most important holidays in China and celebrates the beginning of the new year on the traditional Chinese calendar. The first day of the Chinese New Year was on 25 January 2020. The Chinese New Year is associated with a number of customs; among these is returning home for an annual reunion dinner. Thus, traveling home had already begun by the time Chinese authorities attempted to curtail the spread of the coronavirus by extending the lunar new year holidays and suspending travel. This made control measure of the outbreak more difficult. The net effect of the initial delay in the investigation and the holiday travel was, in effect, the “Perfect Storm.” The results of the spread within China of the SARS‐CoV‐2 are considerable and still unfolding. Given the timing of this outbreak, the inability of the Chinese government's measures to control this epidemic and limit most of these cases to Wuhan is understandable. The question then is, “What's next for China?” As earlier suggested, there remains considerable work to be done. This study includes many issues that can be determined in the short term as well as some that will require long‐term solutions. Some of these issues are as follows. The timing of colonization, infection, and shedding need to be determined. For example, are infected persons first colonized? Do infected persons shed virus before they have clinical symptoms? Transmission characteristics need to be determined. Is infectious transmission limited to respiratory droplets or can the virus be transmitted by contact with an infected person? Efficient human‐to‐human transmission is required for large‐scale spread (ie, an epidemic or pandemic) of any emerging virus. Therefore, the basic reproductive ratio during this epidemic needs to be determined; the basic reproductive ratio is defined as the average number of secondary cases that an infected person produces during their entire infectious period in a susceptible and uninfected population. The case‐fatality rate needs to be accurately determined; the case‐fatality rate of the SARS‐CoV was around 11%. Some of these questions are already being addressed, , but further work is needed. Often serology is required in such an epidemic to determine how many persons may have had clinically inapparent infections. Detection and identification methods that are accurate and can be performed in real time at the point of care or in the field need to be developed. The exact relationship between the SARS‐CoV‐2 and animals (eg, bats) needs to be determined. , , Although bats are suspected, the question of how the virus has moved from bats to the human host needs to be resolved. Does this transmission involve intermediate animal hosts as occurred with SARS‐CoV and MERS‐CoV? If the SARS‐CoV‐2 proves to have an animal sources, the continued presence of live animal markets in China must be seriously questioned. In the long term, the development of vaccines and antiviral therapy needs to be a higher priority than it has been since the SARS pandemic in 2002 to 2003; the lack of a SARS vaccine or SARS antiviral therapy suggests that such research has not been a priority. For example, Ampligen (poly I:poly C124) has been shown to inhibit SARS‐CoV in a murine lung model, yet has not been further evaluated in humans. Similarly, Remdesivir (GS‐5734) has been shown to inhibit both epidemic and zoonotic coronaviruses. It is likely that continued investigation of new antiviral agents with activity against coronaviruses in the absence of ongoing active epidemics would be enhanced by government incentives. Another issue in the long term that needs to be addressed is the potential of novel coronaviruses to spread within medical centers to health care workers as has happened with SARS‐CoV and MERS‐CoV. , , Most medical centers, whether in China or in the United States, are not prepared for such a problem. For example, negative‐pressure containment rooms with proper anterooms are either not found or found only in limited numbers in medical centers in the United States. The recent epidemic in China caused by the SARS‐CoV‐2 is yet another example of emerging zoonotic viral diseases. Like previous epidemics/pandemics caused by novel members of the coronavirus family, there are many lessons to be learned. Much work remains to be done before this latest coronavirus is fully understood and these lessons can be learned.

AUTHOR CONTRIBUTIONS

Concept forming: HL and Y‐WT. Writing: CWS. Revising and editing: HL and Y‐WT.
  26 in total

Review 1.  Perspectives on the basic reproductive ratio.

Authors:  J M Heffernan; R J Smith; L M Wahl
Journal:  J R Soc Interface       Date:  2005-09-22       Impact factor: 4.118

2.  Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice.

Authors:  Dale L Barnard; Craig W Day; Kevin Bailey; Matthew Heiner; Robert Montgomery; Larry Lauridsen; Paul K S Chan; Robert W Sidwell
Journal:  Antivir Chem Chemother       Date:  2006

3.  Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses.

Authors:  Timothy P Sheahan; Amy C Sims; Rachel L Graham; Vineet D Menachery; Lisa E Gralinski; James B Case; Sarah R Leist; Krzysztof Pyrc; Joy Y Feng; Iva Trantcheva; Roy Bannister; Yeojin Park; Darius Babusis; Michael O Clarke; Richard L Mackman; Jamie E Spahn; Christopher A Palmiotti; Dustin Siegel; Adrian S Ray; Tomas Cihlar; Robert Jordan; Mark R Denison; Ralph S Baric
Journal:  Sci Transl Med       Date:  2017-06-28       Impact factor: 17.956

4.  A pneumonia outbreak associated with a new coronavirus of probable bat origin.

Authors:  Peng Zhou; Xing-Lou Yang; Xian-Guang Wang; Ben Hu; Lei Zhang; Wei Zhang; Hao-Rui Si; Yan Zhu; Bei Li; Chao-Lin Huang; Hui-Dong Chen; Jing Chen; Yun Luo; Hua Guo; Ren-Di Jiang; Mei-Qin Liu; Ying Chen; Xu-Rui Shen; Xi Wang; Xiao-Shuang Zheng; Kai Zhao; Quan-Jiao Chen; Fei Deng; Lin-Lin Liu; Bing Yan; Fa-Xian Zhan; Yan-Yi Wang; Geng-Fu Xiao; Zheng-Li Shi
Journal:  Nature       Date:  2020-02-03       Impact factor: 69.504

5.  Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.

Authors:  Roujian Lu; Xiang Zhao; Juan Li; Peihua Niu; Bo Yang; Honglong Wu; Wenling Wang; Hao Song; Baoying Huang; Na Zhu; Yuhai Bi; Xuejun Ma; Faxian Zhan; Liang Wang; Tao Hu; Hong Zhou; Zhenhong Hu; Weimin Zhou; Li Zhao; Jing Chen; Yao Meng; Ji Wang; Yang Lin; Jianying Yuan; Zhihao Xie; Jinmin Ma; William J Liu; Dayan Wang; Wenbo Xu; Edward C Holmes; George F Gao; Guizhen Wu; Weijun Chen; Weifeng Shi; Wenjie Tan
Journal:  Lancet       Date:  2020-01-30       Impact factor: 79.321

6.  Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia.

Authors:  Qun Li; Xuhua Guan; Peng Wu; Xiaoye Wang; Lei Zhou; Yeqing Tong; Ruiqi Ren; Kathy S M Leung; Eric H Y Lau; Jessica Y Wong; Xuesen Xing; Nijuan Xiang; Yang Wu; Chao Li; Qi Chen; Dan Li; Tian Liu; Jing Zhao; Man Liu; Wenxiao Tu; Chuding Chen; Lianmei Jin; Rui Yang; Qi Wang; Suhua Zhou; Rui Wang; Hui Liu; Yinbo Luo; Yuan Liu; Ge Shao; Huan Li; Zhongfa Tao; Yang Yang; Zhiqiang Deng; Boxi Liu; Zhitao Ma; Yanping Zhang; Guoqing Shi; Tommy T Y Lam; Joseph T Wu; George F Gao; Benjamin J Cowling; Bo Yang; Gabriel M Leung; Zijian Feng
Journal:  N Engl J Med       Date:  2020-01-29       Impact factor: 176.079

7.  First Case of 2019 Novel Coronavirus in the United States.

Authors:  Michelle L Holshue; Chas DeBolt; Scott Lindquist; Kathy H Lofy; John Wiesman; Hollianne Bruce; Christopher Spitters; Keith Ericson; Sara Wilkerson; Ahmet Tural; George Diaz; Amanda Cohn; LeAnne Fox; Anita Patel; Susan I Gerber; Lindsay Kim; Suxiang Tong; Xiaoyan Lu; Steve Lindstrom; Mark A Pallansch; William C Weldon; Holly M Biggs; Timothy M Uyeki; Satish K Pillai
Journal:  N Engl J Med       Date:  2020-01-31       Impact factor: 91.245

8.  The Wuhan SARS-CoV-2-What's next for China.

Authors:  Hongzhou Lu; Charles W Stratton; Yi-Wei Tang
Journal:  J Med Virol       Date:  2020-03-18       Impact factor: 2.327

9.  Viral Metagenomics Revealed Sendai Virus and Coronavirus Infection of Malayan Pangolins (Manis javanica).

Authors:  Ping Liu; Wu Chen; Jin-Ping Chen
Journal:  Viruses       Date:  2019-10-24       Impact factor: 5.048

10.  Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle.

Authors:  Hongzhou Lu; Charles W Stratton; Yi-Wei Tang
Journal:  J Med Virol       Date:  2020-02-12       Impact factor: 2.327

View more
  23 in total

1.  The continuing evolution of COVID-19 imaging pathways in the UK: a British Society of Thoracic Imaging expert reference group update.

Authors:  S S Hare; J C L Rodrigues; A Nair; J Jacob; S Upile; A Johnstone; R Mcstay; A Edey; G Robinson
Journal:  Clin Radiol       Date:  2020-04-15       Impact factor: 2.350

2.  Clinical impact of monocyte distribution width and neutrophil-to-lymphocyte ratio for distinguishing COVID-19 and influenza from other upper respiratory tract infections: A pilot study.

Authors:  Hui-An Lin; Sheng-Feng Lin; Hui-Wen Chang; Yuarn-Jang Lee; Ray-Jade Chen; Sen-Kuang Hou
Journal:  PLoS One       Date:  2020-11-02       Impact factor: 3.240

Review 3.  Serological assays and host antibody detection in coronavirus-related disease diagnosis.

Authors:  Sayeh Dowlatshahi; Ehsan Shabani; Mohammad J Abdekhodaie
Journal:  Arch Virol       Date:  2021-01-25       Impact factor: 2.685

Review 4.  An evolving approach to the laboratory assessment of COVID-19.

Authors:  Hongzhou Lu; Charles W Stratton; Yi-Wei Tang
Journal:  J Med Virol       Date:  2020-07-28       Impact factor: 20.693

5.  The Wuhan SARS-CoV-2-What's next for China.

Authors:  Hongzhou Lu; Charles W Stratton; Yi-Wei Tang
Journal:  J Med Virol       Date:  2020-03-18       Impact factor: 2.327

6.  An update on COVID-19 for the radiologist - A British society of Thoracic Imaging statement.

Authors:  J C L Rodrigues; S S Hare; A Edey; A Devaraj; J Jacob; A Johnstone; R McStay; A Nair; G Robinson
Journal:  Clin Radiol       Date:  2020-03-23       Impact factor: 2.350

7.  COVID-19 prognosis: what we know of the significance and prognostic value of liver-related laboratory parameters in SARS-CoV-2 infection.

Authors:  Davood Bashash; Meysam Olfatifar; Farzad Hadaegh; Hamid Asadzadeh Aghdaei; Mohammad Reza Zali
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2020

8.  Hypoxemia Index Associated with Prehospital Intubation in COVID-19 Patients.

Authors:  Romain Jouffroy; Romain Kedzierewicz; Clement Derkenne; Kilian Bertho; Marine Scannavino; Benoit Frattini; Frederic Lemoine; Daniel Jost; Bertrand Prunet
Journal:  J Clin Med       Date:  2020-09-20       Impact factor: 4.241

Review 9.  Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): a review.

Authors:  Wei Feng; Wei Zong; Feng Wang; Shaoqing Ju
Journal:  Mol Cancer       Date:  2020-06-02       Impact factor: 41.444

10.  Ecological Study on Differences in COVID-19 Fatality among Wuhan, Rest of Hubei, and Rest of China.

Authors:  Youfu Ke; Jianli Cui; Yunkeung Wong
Journal:  J Epidemiol Glob Health       Date:  2020-09-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.